NFKB1 and prostate carcinoma: Interestingly, it was recently documented that KIFC2 promotes progression and chemoresistance in prostate cancer by activating the NF-κB signaling pathway (26) and is a potential prognostic biomarker in colon and prostate cancers (24, 25).